In Rb1-deficient tumors—including CDK4/6i-resistant breast cancer—upregulation of mitosis-associated E2F target genes provides a therapeutic opportunity for AURKA inhibitors to trigger replication stress via synthetic lethality, leading to tumor cell death (Gong et al., 2019). Here, RB1 is linked to neoplasm.